Alvogen Recalls Clindamycin Injection Vials Due to Sterility Concerns
Alvogen, Inc. is recalling 5,100 vials of Clindamycin Injection USP due to a lack of assurance of sterility. The affected product was distributed nationwide.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls involving significant injury/property-damage reports or hospitalization reports are rated Severe (4). While specific injury reports are not detailed in the text, the agency classification and the nature of the defect (sterility) align with the Severe criteria for Class II recalls.
Plain-English summary
Alvogen, Inc. is recalling 5,100 2 mL single-dose vials of Clindamycin Injection USP (300 mg/2 mL). The product is identified by Lot 73-154-EV and has an expiration date of 12/31/17. The recall was initiated because of a lack of assurance of sterility.
The affected product was distributed nationwide. The recall is classified as Class II by the U.S. Food and Drug Administration.
Healthcare providers and patients should stop using the affected product and contact their pharmacist or the recalling firm for further instructions.
The recalled product
- Product
- Clindamycin Injection USP; 300 mg/2 mL (150 mg/mL). 2 mL Single-dose ADD-VANTAGE Vial, Rx Only, Manufactured for Alvogen, Inc., Pine Brook, NJ 07058, NDC 47781-462-69
- Manufacturer
- Alvogen, Inc
- Category
- Drug — Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: 73-154-EV
- Exp. 12/31/17
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Alvogen, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Alvogen, Inc
See all →- ModerateCarotid anesthesia kits recalled over recalled B. Braun administration sets inside
FDA (Drugs) · 2026-01-21
- SevereFentanyl Transdermal Patches Recalled for Defective Delivery System
FDA (Drugs) · 2025-02-26
- ModeratePrescription Levothyroxine Sodium Tablets Recalled Due to Sub-Potency
FDA (Drugs) · 2023-03-08
- SevereAlvogen Buprenorphine and Naloxone Sublingual Film recalled for subpotent active ingredients
FDA (Drugs) · 2021-07-14
- ModerateAlvogen Recalls Nitrofurantoin Capsules Due to Failed Dissolution Specifications
FDA (Drugs) · 2019-08-21
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29